New Jersey · 2026-2027 Regular Session · Bill
S 4222: Improves access to lower-cost generic and biosimilar drugs.
In committee Official data
- Introduced
- In committee
- Passed one chamber
- Passed both chambers
- Enacted
Last official action: ·Record last updated:
Plain-language summary
S 4222 is a bill introduced in the New Jersey Senate on May 14, 2026. According to its official title, it concerns: Improves access to lower-cost generic and biosimilar drugs. Primary sponsor: Gordon Johnson (Democratic), John McKeon (Democratic). Most recent recorded action (May 14, 2026): Introduced in the Senate, Referred to Senate Commerce Committee.
Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written
Sponsors
Sponsors by party (alphabetical): Democratic 2
| Name | Role | Party | Chamber | District |
|---|---|---|---|---|
| Gordon Johnson | Primary sponsor | Democratic | Senate | 37 |
| John McKeon | Primary sponsor | Democratic | Senate | 27 |
“Support” is shown only as formal sponsorship recorded by the legislature. Roll-call votes are available on the official bill page.
Recent official actions
- Introduced in the Senate, Referred to Senate Commerce Committee